Asselah, J., & Sperlich, C. (2013). Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. Canadian Urological Association Journal, 7(1-2-S1), S11-S17. https://doi.org/10.5489/cuaj.274